Gastritis Market - Forecast(2020 - 2025)

Report Code: HCR 0925 Report Format: PDF + Excel (Delivery in 48 Hrs)
Gastritis Market Overview
Gastritis Market size is $146m in 2019, growing at a CAGR of 3.67% during the forecast period 2020-2025. Gastritis is the inflammation of gastric mucosa, which is a membrane lining that covers the surface of internal organs and body cavities. The production of mucus, acid and enzymes reduces when the inflammation of the stomach lining takes place. Stomach infection, pepotic uncler, abdominal infection, Irritable bowel syndrome(ibs), diarrhea or constipation types of gastritis conditions and its symptoms are upper abdominal discomfort, vomiting, nausea and others. Gastritis is caused by the bacteria helicobacter pylori or by the use of non-steroidal anti-inflammatory drugs, irritation due to excessive alcohol use, chronic vomiting, stress or the use of certain medications such as aspirin or other anti-inflammatory drugs.
 
Report Coverage
The report: “Gastritis Market – Forecast (2020-2025)”, by IndustryARC covers an in-depth analysis of the following segments of the Gastritis Market. 

By Type: Acute Gastritis, Chronic Gastritis, Erosive Gastritis and Non-Erosive Gastritis.
By Drugs Type: Clarithromycin (Biaxin), Metronidazole (Flagyl), Lansoprazole (Prevacid), Esomeprazole (Nexium), Famotidine (Pepcid) and Others.
By Product Type: Antibiotics, Histamine Blockers, Antibiotics and Acid-Blocking Medications.
By End User: Hospitals/Clinics, Pharmaceuticals, Diagnostic Centers and Others. 
By Geography: North America, Europe, Asia-Pacific and Rest of the World.

Key Takeaways
  • Increasing awareness amongst people for early treatment of disease is set to propel the growth of the market. 
  • Increase in the unhealthy habits of people is the driving factors for the growth of Gastritis market.
  • Increased geriatric population along with gastric carcinoma and increased risk of heart attack in elderly aiding growth towards the market.
  • Europe region is estimated to record the fastest growth rate during the forecast period 2020-2025.

By Type - Segment Analysis
In 2019, Acute Gastritis segment dominated the Gastritis Market in terms of revenue is estimated to grow at a CAGR of 3.1%. Acute Gastritis is caused due  the overuse of Non-Steroidal Anti-Inflammatory (NSAID) drugs like ibuprofen, sodium naproxen, and diclofenac including complications such as hemorrhages and erosion. It is diagnosed by antacids like famotidine (Pepcid) and proton pump inhibitors that helps in the suppression excessive acid production abetting towards the market’s growth.

Geography - Segment Analysis
In 2019, the North America region dominated Gastritis Market in terms of revenue with a market share of 39% owing towards the presence of established in this region. This growth can be attributed towards the increasing research & development initiatives and government support for the improvement of the healthcare sector. The increasing awareness about the health and availability of new treatment methods drives the market in this region is key factors in the growth of the Gastritis market. Europe is estimated to record the fastest growth rate during the forecast period 2020-2025. 

Drivers – Gastritis Market

  • Increasing In The Prevalence of Geriatric Population
The increasing number of lactose-intolerant issues, NSAID or alcohol use vulnerability to falling prey of gastritis is more likely to lead to an increasing number of gastritis cases. The rise in the population leading towards increased risk of heart attack. Government focusing on the drug development for the reduction of diseases is the other major factor driving growth. Increasing healthcare expenditure by various countries is also contributing to the market growth.

Challenges – Gastritis Market

  • Side Effects
Side-effects such as depression, sleep disorders, and incontinence hampering the market’s growth. Antibiotic resistance and lack of patient compliance are main factors restraining the market’s growth.

Gastritis Industry Outlook 
Product Launches was the key strategy of the players in the Gastritis Industry. Gastritis top 10 companies include Takeda Pharmaceutical Company Ltd, PERNIX Therapeutics, Perrigo Pharmaceutical, Teva Pharmaceutical, Medtronic PLC, Pfizer Inc., Novartis AG, Qiagen NV, AstraZeneca plc. and Thermo Fisher Scientific Inc.

Acquisitions/Product Launches
  • In August 2016, Teva Pharmaceuticals acquired Allergan’s generics business. This acquisition helped the company in delivering the highest-quality medicines at the most competitive prices, unlocking value to patients, healthcare systems and investors around the world. 
  • In January 2019, Takeda Pharmaceutical Company Ltd acquired Shire plc. This acquisition helped the company in accelerating transformation journey to deliver highly-innovative medicines to patients around the world with expanded scale and geographical footprint. 

1. Gastritis Market Overview
    1.1 Definitions and Scope
2. Gastritis Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Type
    2.3 Key trends by Drug Type
    2.4 Key trends by Geography
3. Gastritis Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Gastritis Market - Startup Companies Scenario (Premium)
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Gastritis Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Gastritis Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters Five Force Model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Gastritis Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Gastritis Market – By Type (Market Size –$Million/$Billion)
    8.1 Acute Gastritis
    8.2 Chronic Gastritis
    8.3 Erosive Gastritis
    8.4 Non-Erosive Gastritis
9. Gastritis Market – By Drug Type (Market Size –$Million/$Billion)
    9.1 Clarithromycin (Biaxin)
    9.2 Metronidazole (Flagyl)
    9.3 Lansoprazole (Prevacid)
    9.4 Esomeprazole (Nexium)
    9.5 Famotidine (Pepcid)
    9.6 Others
10. Gastritis Market – By Product Type (Market Size –$Million/$Billion)
    10.1 Antibiotics
    10.2 Histamine Blockers
    10.3 Antibiotics
    10.4 Acid-Blocking Medications
11. Gastritis Market – By End User (Market Size –$Million/$Billion)
    11.1 Hospitals/Clinics
    11.2 Pharmacy 
    11.3 Home Care
    11.4 Others 
12. Gastritis Market - By Geography (Market Size –$Million/$Billion)
    12.1 North America
        12.1.1 U.S.
        12.1.2 Canada
        12.1.3 Mexico
    12.2 Europe
        12.2.1 U.K.
        12.2.2 Germany
        12.2.3 France
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Rest of Europe
    12.3 Asia-Pacific
        12.3.1 China
        12.3.2 India
        12.3.3 Japan
        12.3.4 South Korea
        12.3.5 Australia & New Zealand
        12.3.6 Rest of Asia-Pacific
    12.4 Rest of the World
        12.4.1 Middle East
        12.4.2 Africa
        12.4.3 South America
13. Gastritis Market - Entropy
14. Gastritis Market – Industry/Segment Competition Landscape (Premium)
    14.1 Market Share Analysis
        14.1.1 Global Market Share – Key Companies
        14.1.2 Market Share by Region – Key companies
        14.1.3 Market Share by Countries – Key Companies
        14.1.4 Best Practices for Companies
15. Gastritis Market – Key Company List by Country Premium Premium
16. Gastritis Market Company Analysis
    16.1 Company 1
    16.2 Company 2
    16.3 Company 3
    16.4 Company 4
    16.5 Company 5
    16.6 Company 6
    16.7 Company 7
    16.8 Company 8
    16.9 Company 9
    16.10 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.